Hélène Cavé and colleagues genetically profile a cohort of 118 juvenile myelomonocytic leukemia (JMML) samples and uncover mutations in multiple components of the RAS signaling pathway and the PRC2 network. Their study demonstrates an association between JMML clinical outcome and mutational profile and suggests a dose-dependent effect for RAS pathway activation.
- Aurélie Caye
- Marion Strullu
- Hélène Cavé
